Company news: Jazz Pharmaceuticals, WebMD

Share this article:
FDA slapped Jazz Pharmaceuticals with a warning letter for a DTC patient brochure plugging schizophrenia drug FazaClo. The brochure, said FDA, omits and minimizes important risk info, broadens the approved indication, presents unsubstantiated superiority claims and overstates efficacy in a way that is “concerning from a public health perspective because they suggest that FazaClo is safer and more effective than has been demonstrated.” FazaClo is a legacy product of Azur, which Jazz acquired last year.

A survey by Makovsky Health and Kelton found consumers overwhelmingly prefer to search for health info on PCs (90%) rather than smartphones (7%) or tablets (4%). The survey of 1,000 consumers also found that consumers regard user-generated content on Wikipedia as a credible source, and that more than half use WebMD, while nearly a third visit online health mags like Prevention and Women's Health. Social networks are far less popular for health info, with Facebook used by 17% of those polled and YouTube by 15%.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.